Search Results - "Leung, Rainbow Wing Hei"
-
1
Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer
Published in Cell death & disease (03-02-2024)“…Hepatocellular carcinoma (HCC) is an aggressive malignancy without effective therapeutic approaches. Here, we evaluate the tumor-intrinsic mechanisms that…”
Get full text
Journal Article -
2
Wnt/β-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma
Published in Cancers (07-11-2022)“…Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide due to its high rates of tumor recurrence and metastasis. Aberrant Wnt/β-catenin…”
Get full text
Journal Article -
3
Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma
Published in Nature communications (23-10-2023)“…Increasing evidence has demonstrated that drug resistance can be acquired in cancer cells by kinase rewiring, which is an obstacle for efficient cancer…”
Get full text
Journal Article -
4
Hampering Stromal Cells in the Tumor Microenvironment as a Therapeutic Strategy to Destem Cancer Stem Cells
Published in Cancers (25-06-2021)“…Cancer stem cells (CSCs) within the tumor bulk play crucial roles in tumor initiation, recurrence and therapeutic resistance. In addition to intrinsic…”
Get full text
Journal Article -
5
Identification of KCTD17 as a RAS stabilizer in hepatocellular carcinoma
Published in Clinical and molecular hepatology (30-08-2024)Get full text
Journal Article -
6
EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma
Published in Cancer research (Chicago, Ill.) (15-06-2021)“…The survival benefit derived from sorafenib treatment for patients with hepatocellular carcinoma (HCC) is modest due to acquired resistance. Targeting cancer…”
Get full text
Journal Article -
7
UBE2T: A new molecular regulator of cancer stemness in hepatocellular carcinoma
Published in Oncotarget (17-08-2021)Get full text
Journal Article -
8
Abstract 395: Resistance to tyrosine kinase inhibitor confers an immunosuppressive microenvironment and cross-resistance to immunotherapy through AXL/PDPK1 axis in liver cancer
Published in Cancer research (Chicago, Ill.) (04-04-2023)“…Abstract Systemic therapy is the current standard of care for unresectable advanced hepatocellular carcinoma (HCC), the most malignant form of liver cancer…”
Get full text
Journal Article -
9
SCYL3, as a novel binding partner and regulator of ROCK2, promotes hepatocellular carcinoma progression
Published in JHEP reports (01-01-2023)“…SCY1-like pseudokinase 3 (SCYL3) was identified as a binding partner of ezrin, implicating it in metastasis. However, the clinical relevance and functional…”
Get full text
Journal Article